Stay updated with breaking news from Small Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Total revenues of $919 million in the third quarter – Jakafi® net product revenues of $636 million in Q3'23, $1.9 billion YTD 2023, driven by growth in total patients across all...
On June 30, 2023, the Centers for Medicare and Medicaid Services (CMS) released its much-anticipated final guidance ("Final Guidance") for the Medicare Drug Price Negotiation Program...
Dr. Richard Katz Discusses Bridging the Gap between Academia, Small ...
The Centers for Medicare & Medicaid Services (CMS) recently issued initial guidance describing CMS’s plans for implementation of the new Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and how CMS intends to implement the new program, with a focus on the details that apply for 2026, the first year that negotiated prices will be available under this new program.